Nama's AI scorecard currently rates Artivion Sell (2.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AORT's P/E ratio?

Artivion trades at a trailing price-to-earnings ratio of 55.1.

When does AORT report earnings?

Artivion's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $0.12.

What is the AORT price target?

The median analyst price target from 9 analysts is $40.00, with a range of $31.00 – $48.00.

Is AORT Shariah compliant?

Nama's AAOIFI-style screen reads Artivion as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.

Nama Insights

Artivion (AORT)

Healthcare · Medical Devices · NYSE

Artivion (AORT) is a Healthcare company in the Medical Devices industry. It has a market capitalization of $1.23B, a trailing price-to-earnings ratio of 55.1 and a free-cash-flow yield of 0.1%. Over the most recent reported fiscal year, revenue grew 13.6% and free cash flow per share fell 93.3%. Nama's AI scorecard rates it Sell, 2.6 out of 10. On 12-month momentum it ranks in the trailing band of its market.

AI scorecard

Sell · 2.6/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Trailing · -54.5% over 12 months ex. last

Bottom 20% of its market on the past year's move.

Shariah screen

Shariah Compliant

Passes our debt, cash and income screen; not a scholar's ruling.

Off its high

-58.1%

How far the last close sits under the highest price of the past five years.

Market cap	$1.23B
Trailing P/E	55.1
Price / book	2.8
Price / sales	2.6
FCF yield	0.1%
Dividend yield	—
Gross margin	64.4%
Operating margin	2.9%
Net margin	-0.7%
Revenue growth (YoY)	+13.6%
Revenue growth (3-yr annual)	+12.0%
EPS growth (YoY)	—
FCF/share growth (YoY)	-93.3%
Beta	1.2
Exchange	NYSE
Sector	Healthcare
Industry	Medical Devices

AORT earnings

Next report: Feb 11, 2027 (Q4 2026, EPS estimate $0.12). Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 5, 2026	$0.08	$0.07	+14.3%	—
Q2 2026	Aug 6, 2026	$0.13	$0.10	+30.0%	$125.76M
Q1 2026	May 7, 2026	$0.08	$0.12	-33.3%	$116.34M
Q4 2025	Feb 12, 2026	$0.17	$0.18	-5.6%	$115.99M

AORT analyst price target

Median target $40.00 from 9 analysts, ranging $31.00 – $48.00.

Medical Devices peers

Ticker	Company	Market cap	P/E
ABT	Abbott Laboratories	$190.39B	20.4
MDT	Medtronic	$130.22B	17.8
SYK	Stryker	$124.06B	22.8
BSX	Boston Scientific	$61.96B	13.4
EW	Edwards Lifesciences	$58.73B	34.7
GEHC	GE HealthCare Technologies	$37.25B	16.8
PHG	Koninklijke Philips	$29.67B	15.2
DXCM	DexCom	$29.62B	29.7

Explore live AORT data on Nama Insights →

Recent Congressional trades

Artivion trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023

AORT FAQ

Is AORT a buy?: Nama's AI scorecard currently rates Artivion Sell (2.6 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AORT's P/E ratio?: Artivion trades at a trailing price-to-earnings ratio of 55.1.
When does AORT report earnings?: Artivion's next scheduled report is on Feb 11, 2027. Analysts expect EPS of $0.12.
What is the AORT price target?: The median analyst price target from 9 analysts is $40.00, with a range of $31.00 – $48.00.
Is AORT Shariah compliant?: Nama's AAOIFI-style screen reads Artivion as Shariah Compliant. Passes our debt, cash and income screen; not a scholar's ruling.